219 related articles for article (PubMed ID: 17226906)
1. Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease.
Colecchia A; Vestito A; Pasqui F; Mazzella G; Roda E; Pistoia F; Brandimarte G; Festi D
World J Gastroenterol; 2007 Jan; 13(2):264-9. PubMed ID: 17226906
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial.
Papi C; Ciaco A; Koch M; Capurso L
Aliment Pharmacol Ther; 1995 Feb; 9(1):33-9. PubMed ID: 7766741
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular disease.
Bianchi M; Festa V; Moretti A; Ciaco A; Mangone M; Tornatore V; Dezi A; Luchetti R; De Pascalis B; Papi C; Koch M
Aliment Pharmacol Ther; 2011 Apr; 33(8):902-10. PubMed ID: 21366632
[TBL] [Abstract][Full Text] [Related]
4. Rifaximin in the management of colonic diverticular disease.
Latella G; Scarpignato C
Expert Rev Gastroenterol Hepatol; 2009 Dec; 3(6):585-98. PubMed ID: 19929580
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of rifaximin on symptoms of uncomplicated diverticular disease of the colon. A pilot multicentre open trial. Diverticular Disease Study Group.
Papi C; Ciaco A; Koch M; Capurso L
Ital J Gastroenterol; 1992 Oct; 24(8):452-6. PubMed ID: 1330083
[TBL] [Abstract][Full Text] [Related]
6. [Role of rifaximin in the treatment of colonic diverticular disease].
Moretti A; Spagnolo A; Mangone M; Chiesara F; Aratari A; Papi C; Koch M
Clin Ter; 2012; 163(1):33-8. PubMed ID: 22362232
[TBL] [Abstract][Full Text] [Related]
7. Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon.
Latella G; Pimpo MT; Sottili S; Zippi M; Viscido A; Chiaramonte M; Frieri G
Int J Colorectal Dis; 2003 Jan; 18(1):55-62. PubMed ID: 12458383
[TBL] [Abstract][Full Text] [Related]
8. Quality of life in uncomplicated symptomatic diverticular disease: is it another good reason for treatment?
Comparato G; Fanigliulo L; Aragona G; Cavestro GM; Cavallaro LG; Leandro G; Pilotto A; Nervi G; Soliani P; Sianesi M; Franzé A; Di Mario F
Dig Dis; 2007; 25(3):252-9. PubMed ID: 17827951
[TBL] [Abstract][Full Text] [Related]
9. Prevention of complications and symptomatic recurrences in diverticular disease with mesalazine: a 12-month follow-up.
Comparato G; Fanigliulo L; Cavallaro LG; Aragona G; Cavestro GM; Iori V; Maino M; Mazzocchi G; Muzzetto P; Colla G; Sianesi M; Franzé A; Mario FD
Dig Dis Sci; 2007 Nov; 52(11):2934-41. PubMed ID: 17410435
[TBL] [Abstract][Full Text] [Related]
10. Non-interventional study evaluating efficacy and tolerability of rifaximin for treatment of uncomplicated diverticular disease.
Stallinger S; Eller N; Högenauer C
Wien Klin Wochenschr; 2014 Jan; 126(1-2):9-14. PubMed ID: 24240607
[TBL] [Abstract][Full Text] [Related]
11. Rifaximin and diverticular disease: Position paper of the Italian Society of Gastroenterology (SIGE).
Cuomo R; Barbara G; Annibale B
Dig Liver Dis; 2017 Jun; 49(6):595-603. PubMed ID: 28215517
[TBL] [Abstract][Full Text] [Related]
12. Cyclic antibiotic therapy for diverticular disease: a critical reappraisal.
Zullo A; Hassan C; Maconi G; Manes G; Tammaro G; De Francesco V; Annibale B; Ficano L; Buri L; Gatto G; Lorenzetti R; Campo SM; Ierardi E; Pace F; Morini S
J Gastrointestin Liver Dis; 2010 Sep; 19(3):295-302. PubMed ID: 20922195
[TBL] [Abstract][Full Text] [Related]
13. Rifaximin plus mesalazine followed by mesalazine alone is highly effective in obtaining remission of symptomatic uncomplicated diverticular disease.
Brandimarte G; Tursi A
Med Sci Monit; 2004 May; 10(5):PI70-3. PubMed ID: 15114281
[TBL] [Abstract][Full Text] [Related]
14. Combined therapy: rifaximin-α and arabinogalactan with lactoferrin combination effectively prevents recurrences of symptomatic uncomplicated diverticular disease.
Pietrzak AM; Banasiewicz T; Skoczylas K; Dziki A; Szczepkowski M
Pol Przegl Chir; 2020 Apr; 92(2):22-28. PubMed ID: 32312914
[TBL] [Abstract][Full Text] [Related]
15. Interaction between rifaximin and dietary fibre in patients with diverticular disease.
D'Incà R; Pomerri F; Vettorato MG; Dal Pont E; Di Leo V; Ferronato A; Medici V; Sturniolo GC
Aliment Pharmacol Ther; 2007 Apr; 25(7):771-9. PubMed ID: 17373915
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of mesalazine in the treatment of symptomatic diverticular disease.
Di Mario F; Aragona G; Leandro G; Comparato G; Fanigliulo L; Cavallaro LG; Cavestro GM; Iori V; Maino M; Moussa AM; Gnocchi A; Mazzocchi G; Franzé A
Dig Dis Sci; 2005 Mar; 50(3):581-6. PubMed ID: 15810646
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis of symptomatic uncomplicated diverticular disease and the role of Rifaximin in management.
Maconi G
Acta Biomed; 2017 Apr; 88(1):25-32. PubMed ID: 28467330
[TBL] [Abstract][Full Text] [Related]
18. Treatment of diverticular disease of the colon and prevention of acute diverticulitis: a systematic review.
Maconi G; Barbara G; Bosetti C; Cuomo R; Annibale B
Dis Colon Rectum; 2011 Oct; 54(10):1326-38. PubMed ID: 21904150
[TBL] [Abstract][Full Text] [Related]
19. One year intermittent rifaximin plus fibre supplementation vs. fibre supplementation alone to prevent diverticulitis recurrence: a proof-of-concept study.
Lanas A; Ponce J; Bignamini A; Mearin F
Dig Liver Dis; 2013 Feb; 45(2):104-9. PubMed ID: 23092785
[TBL] [Abstract][Full Text] [Related]
20. Rifaximin in diverticulosis and diverticular disease: a national survey among Italian gastroenterologists and general practitioners.
Gatta L; Bellini M; Scarpignato C; Marrocco W; Chiriatti A; Grosso A; Lambiase C; Usai-Satta P; Vassallo R; Bartoletti P; Monica F; Manta R; Scotti S; Soncini M;
Intern Emerg Med; 2024 Jun; ():. PubMed ID: 38850356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
